News

Atavistik Bio Unveils Promising Treatments for MPNs at ASH 2025

Atavistik Bio Unveils Promising Treatments for MPNs at ASH 2025

Atavistik Bio Presents Innovative Findings at ASH 2025

Atavistik Bio is set to reveal groundbreaking results concerning its development of novel allosteric JAK2 V617F selective inhibitors. These inhibitors aim at effectively treating myeloproliferative neoplasms (MPNs) while sparing normal JAK2 activity, thereby reducing complications. This major announcement will take place at the upcoming ASH Annual Meeting and Exhibition.

The Challenge of Myeloproliferative Neoplasms

Myeloproliferative neoplasms are a group of blood cancers that arise due to the uncontrolled growth of blood cells in the bone marrow. Among these, the JAK2 V617F mutation represents a critical target for therapeutic interventions. Approximately 95% of patients with polycythemia vera, around 60% with essential thrombocythemia, and 55% with myelofibrosis carry this mutation. These statistics highlight the pressing need for effective treatments that specifically address this mutation.

Introducing Allosteric Inhibitors

The innovative inhibitors being developed by Atavistik Bio are designed to specifically target the mutant JAK2 V617F and inhibit its activity without affecting the wild-type JAK2. This selective approach promises to minimize the adverse effects commonly associated with pan-JAK inhibitors, which can indiscriminately inhibit both mutant and normal JAK2 activity, leading to various complications.

Preclinical Data Highlights

Preclinical studies have shown that Atavistik's JAK2 V617F mutant-selective inhibitors exhibit remarkable potency, demonstrating picomolar affinity towards the JAK2 V617F mutant. This drug candidate was created through a sophisticated structure-based drug design process, showcasing over 100-fold selectivity against other kinases in the JAK family.

Mechanism of Action

The unique mechanism of these inhibitors allows them to bind specifically to the allosteric pseudokinase JH2 domain of JAK2. In cellular models, they have shown powerful inhibition of signaling pathways dependent on the JAK2 V617F mutation while sparing cells expressing normal JAK2. This precision is crucial for improving patient outcomes in terms of both efficacy and safety.

Clinical Development and Future Directions

Atavistik Bio is advancing these compounds into further development based on their favorable pharmacokinetic properties and tolerability. The promising results observed in early trials pave the way for exploring these inhibitors in clinical settings, focusing on creating effective treatment protocols for patients suffering from MPNs.

Insights from Atavistik Bio Leadership

“We are excited to showcase our findings at the ASH meeting,” stated Marion Dorsch, Ph.D., President and Chief Scientific Officer at Atavistik Bio. “Our highly selective allosteric inhibitors represent a significant advancement over existing treatments, aiming to provide long-term benefits while reducing the risk of hematological side effects.”

Details of the ASH Presentation

At the ASH Annual Meeting, Atavistik Bio will deliver a presentation titled “Discovery of JAK2 V617F Mutant-Specific Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms”. This will be featured during Session 631, focused on Myeloproliferative Syndromes and Chronic Myeloid Leukemia. The presentation is scheduled for December 6, 2025.

About Atavistik Bio

Atavistik Bio is a clinical-stage biotechnology firm concentrating on the discovery and development of transformative therapeutics targeting severe unmet patient needs. Their innovative approach leverages allostery to create a pipeline of promising therapeutic candidates. Currently, Atavistik is advancing various products, including ATV-1601, an allosteric selective inhibitor designed for solid tumors.

Contact Information

For media inquiries, please contact:
Liz Melone
Melone Communications, LLC
Email: liz@melonecomm.com

Frequently Asked Questions

1. What are JAK2 V617F selective inhibitors?

They are therapeutic agents specifically targeting the JAK2 V617F mutation, aiming to treat related blood cancers while minimizing side effects.

2. How do these inhibitors differ from pan-JAK inhibitors?

Unlike pan-JAK inhibitors, which affect both mutant and normal JAK2, these selective inhibitors focus solely on the mutant, reducing adverse effects.

3. What is myeloproliferative neoplasm?

It’s a type of blood cancer involving the overproduction of blood cells due to mutations in blood stem cells.

4. When will the findings be presented?

The findings will be shared at the ASH Annual Meeting on December 6, 2025.

5. What is the mission of Atavistik Bio?

Atavistik Bio aims to develop innovative allosteric therapeutics to address serious health conditions and improve patient outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 86

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 90

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 22

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 24

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 82

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 95

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading

Top 5 Most Recently Viewed Articles

Yourway Learning Raises $9 Million for Innovative AI Solutions

Updated Category News Views 261

Yourway Learning Secures $9 Million in Funding Yourway Learning has successfully closed a $9 million equity funding round, a significant boost aimed at pushing forward its mission of enhancing K-12 education through innovative AI solutions. The company's focus is on providing trusted, teacher-centered technology that addresses the unique challenges of modern educational...

Continue Reading
Investors Complain: Oddity Tech Ltd. Faces Class Action Allegations

Updated Category News Views 97

Concerns for Investors of Oddity Tech Ltd. Oddity Tech Ltd. (NASDAQ: ODD) is currently under scrutiny. Rosen Law Firm, a prominent global law firm focused on protecting investor rights, has alerted shareholders about a class action lawsuit that has been filed on their behalf. This lawsuit includes all individuals who bought Oddity's securities within a specific timeline,...

Continue Reading
Critical Update on aTyr Pharma's Securities Class Action

Updated Category News Views 219

Understanding the Class Action Lawsuit Against aTyr Pharma Investors should be aware of an ongoing securities class action lawsuit involving aTyr Pharma, Inc. (NASDAQ: ATYR), which highlights the importance of understanding legal proceedings that may impact financial interests. This lawsuit has garnered attention due to its implications for shareholders who acquired...

Continue Reading
Ping An Good Doctor's Robust Growth and Future Strategies Unveiled

Updated Category News Views 303

Ping An Good Doctor's Impressive Interim Performance Ping An Healthcare and Technology Company Limited (Stock Code: 1833.HK) has released its interim results, showcasing a remarkable performance for the first half of 2025. The company has reported total revenue reaching RMB2.5 billion, which reflects a substantial year-on-year increase of 19.5%. Moreover, the net profit...

Continue Reading
Revolutionizing Road Safety: The All-New Auto Air Pump

Updated Category News Views 171

Introducing the Auto Air Pump: A Solution for Flat Tires In an ever-evolving world where travel plays a vital role, ensuring safe and reliable journeys is of utmost importance. Few events are as frustrating as dealing with a flat tire, especially when help is far away. The Auto Air Pump has been designed to address this issue effectively. This compact yet powerful tire...

Continue Reading